View Older Stories View More Recent Stories
-
Emergent BioSolutions board member Sullivan retires after 19 years
-
Emergent BioSolutions (EBS) Tops Q3 EPS by 101c
-
H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)
-
Emergent BioSolutions receives $29 million international order
-
H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)
-
Emergent BioSolutions gets $17 million contract for smallpox drug
-
H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)
-
Emergent BioSolutions gets $56 million U.S. contract for smallpox vaccine
-
H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)
-
Emergent BioSolutions (EBS) Tops Q2 EPS by 26c
-
Emergent BioSolutions receives $51.9 million contract for smallpox treatment
-
Emergent BioSolutions (EBS) Expands NARCANDirect to Offer KLOXXADO Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
-
Emergent BioSolutions (EBS) Secures $62.4M Contract Modification for BAT
-
Emergent BioSolutions (EBS) Added to Russell 3000 Index
-
Emergent BioSolutions (EBS) Tops Q1 EPS by 22c
-
Emergent BioSolutions (EBS) Announces Stock Repurchase Program
-
Emergent BioSolutions (EBS) Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
-
Emergent BioSolutions (EBS) Announces Approximately $27M in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
-
Emergent BioSolutions (EBS) Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
-
H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)
-
After-hours movers: Okta, GitLab, New Fortress Energy, Emergent BioSolutions
-
Emergent BioSolutions (EBS) Tops Q4 EPS by 46c
-
H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)
-
Emergent BioSolutions (EBS) Gains Exclusive Commercial Rights to KLOXXADO Nasal Spray from Hikma Pharmaceuticals
-
Emergent BioSolutions (EBS) Receives Contract Option Valued at Approximately $16.7M to Continue Development Collaboration with BARDA on Ebanga
-
Emergent BioSolutions (EBS) Announces Exercise of $20M Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
-
H.C. Wainwright Starts Emergent BioSolutions (EBS) at Buy
-
Emergent BioSolutions (EBS) Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS
-
Emergent BioSolutions (EBS) PT Raised to $12 at Benchmark
-
Emergent BioSolutions (EBS) Tops Q3 EPS by $1.27
-
Emergent BioSolutions (EBS) Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
-
Emergent BioSolutions (EBS) Appoints Simon Lowry as Chief Medical Officer, Head of R&D
-
Emergent BioSolutions (EBS) Announces Closing of $100 Million Asset-Backed Loan Facility
-
Emergent BioSolutions (EBS) Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA to Support National Preparedness Efforts
-
Emergent (EBS) Climbs 12% After it Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
-
Emergent BioSolutions (EBS) Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
-
Emergent BioSolutions (EBS) to Settle Securities Class Action Litigation
-
Emergent BioSolutions (EBS) Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga Treatment for Ebola
-
Emergent BioSolutions (EBS) Successfully Refinances Debt, Strengthens Financial Profile
-
Increasing unusual call option volume: LUNR K EBS FLR DG ESTC DINO ICLN
-
Emergent BioSolutions (EBS) Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
-
Emergent BioSolutions (EBS) ACAM2000 Receives U.S. FDA Approval for Mpox Indication
-
Emergent BioSolutions (EBS) Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
-
Emergent BioSolutions (EBS) Responds to Mpox Public Health Emergency as Cases Surge in Africa
-
Mpox-linked stocks extend rally into second week
-
Emergent BioSolutions (EBS) Misses Q2 EPS by 137c; offers guidance
-
Emergent BioSolutions (EBS) Expands NARCAN Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
-
Emergent BioSolutions (EBS) Announces Shelf-Life Extension for NARCAN Nasal Spray in Canada
-
Emergent BioSolutions (EBS), Johnson & Johnson (JNJ) Settle Claims Over Vaccine Manufacturing Pact - Bloomberg
-
Emergent BioSolutions (EBS) Wins $250M+ in US Govt Contract Modifications
